Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Supreme Court Doesn't Bite On Amarin Appeal In Omega-3 Fair Trade Complaint

11 Dec 2019

• By Malcolm Spicer

Amarin

Related Content

'That's Huge, Folks': Amarin's Vascepa Cuts CV Risk By 25% On Top Of Statins

25 Sep 2018

FDA Objects To Amarin Trade Complaint Against Omega-3 Ingredients

11 Oct 2017

Amarin Heads Into Vascepa Expansion Labeling Talks After Positive US FDA Panel Review

15 Nov 2019

Amarin's Omega-3 Fair Trade Complaint Questions US Dietary Ingredient Standards

07 Sep 2017

Omega-3 Firms Parse Amarin's Fair Trade Complaint Into Tariff Act Questions

06 Nov 2019

Amarin's Asking ITC To Do FDA's Job, Federal Attorneys Tell Supreme Court

06 Nov 2019

Court Tosses Amarin Fair Trade Complaint Against Omega-3 Imports

03 May 2019

Amarin: Complaint Of Unfair Competition From Omega-3 Supplements 'Ripe' For Supreme Court

01 Aug 2019

Amarin CEO: Consumers Have Heard About Omega-3 Heart Benefits 'Too Long'

06 Sep 2019

Related Companies

Amarin Corp plc

Additional Topics

International United States Dietary Supplements Legal Issues FDA Advertising, Marketing & Sales Commercial Companies Enforcement Distribution Manufacturing Policy Regulation Cardiovascular Consumer

More from Legal

More from Policy & Regulation

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.